Introduction {#S1}
============

Glomerular kidney diseases are autoimmune disorders manifesting either as asymptomatic proteinuria or erythrocyturia, nephrotic or nephritic syndrome. Adult patients with glomerular kidney diseases were found to have increased cardiovascular morbidity and mortality \[[@ref1]\]. In our previous studies we have revealed increased peripheral and central blood pressure \[[@ref2]\], increased arterial stiffness \[[@ref2], [@ref3]\], and increased common carotid artery intima-media thickness \[[@ref2], [@ref4]\] in pediatric patients with glomerulopathies. The pathophysiology of increased cardiovascular damage in these patients remains uncertain, but may be at least partially caused by increased sympathetic tone, hyperlipidemia, and side effects of the treatment.

Idiopathic nephrotic syndrome (INS) is the most common form of nephrotic syndrome in children characterized by normal renal function and blood pressure, isolated proteinuria, relapsing course, and usually good response to steroids \[[@ref5]\]. IgA nephropathy is the most common glomerulonephritis and Henoch-Schönlein purpura is the most common form of vasculitis in pediatric patients. Renal involvement (Henoch-Schönlein nephropathy -- HSN) is reported in 20-60% of affected children. IgAN and HSN are considered to be different manifestations of one disease with deposition of immune complexes containing immunoglobulin A and with the same galactose-deficient IgA1-oriented pathogenesis \[[@ref6]\].

Evaluation of subclinical target-organ damage in children requires expensive equipment, experienced personnel, is time-consuming and, commonly, operator-dependent. Hence, research has been conducted aimed at finding serological markers of increased cardiovascular burden. Adult population studies and pilot pediatric reports suggest that asymmetric dimethylarginine (ADMA) could be one of such biomarkers \[[@ref7], [@ref8]\].

ADMA is a methylated L-arginine derivative produced by all nucleated cells. The main source of ADMA are L-arginine-rich proteins, previously methylated during post-translational modifications (e.g. histones). Once synthesized, ADMA migrates into the extracellular space and into bloodstream, where it exerts its biological actions. ADMA is eliminated from bloodstream through urine excretion and metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). ADMA is an endogenous inhibitor of nitric oxide synthesis by competitive inhibition of L-arginine uptake by endothelial cells \[[@ref9], [@ref10]\]. Numerous studies in adult population showed positive relation between ADMA and both intermediate end-points \[[@ref7], [@ref8]\] as well as cardiovascular morbidity and mortality \[[@ref11], [@ref12]\]. There are limited data on usefulness of ADMA assessment in children with nephrotic syndrome \[[@ref13]\], hypertension \[[@ref14]\], juvenile idiopathic arthritis \[[@ref15]\], and chronic kidney disease \[[@ref16], [@ref17]\].

The primary aim of our study was to establish the significance of ADMA as a biomarker of subclinical arterial damage in children with two most common glomerular kidney diseases, INS and IgAN/HSN. The secondary aim was to find a relation between serum ADMA concentration and clinical and biochemical parameters in these patients.

Material and methods {#S2}
====================

In this cross-sectional study, we analyzed data of 80 children with glomerular kidney diseases (INS and IgAN/HSN patients) treated at one tertiary center of pediatric nephrology. The enrollment took place between October 2013 and May 2016. The inclusion criteria were: age 5-18 years and biopsy-proven IgAN/HSN or unquestionable clinical diagnosis of INS \[[@ref4], [@ref5]\]. The exclusion criteria were: chronic kidney disease (CKD) stage 4 or 5 according to KDIGO \[[@ref18]\], diabetes mellitus, liver, heart, or arterial diseases, and acute infections (temporary exclusion). Patients with INS were examined in the remission of the disease (≥ 3 days without proteinuria), except for drug-resistant patients in whom remission could not have been achieved. The indications to kidney biopsy in INS patients were: age at onset \< 1 year or \> 10 years, steroid resistance, renal dysfunction, and clinical course or biochemical tests suggestive of other glomerulopathy \[[@ref4], [@ref5]\].

Venous peripheral blood was collected after overnight fasting, centrifuged to obtain serum, frozen and stored at --80°C until analysis. ADMA concentration was measured in serum using commercially available enzyme-linked immunosorbent assay (ELISA) (DRG Instruments GmbH, Marburg, Germany) (nmol/ml).

Following clinical data were collected: type of glomerular kidney disease: INS/IgAN/HSN, age (years), sex, body mass index (BMI) *Z*-score \[[@ref19]\], disease vintage (year), number of relapses (patients with INS), kidney biopsy findings, presence of arterial hypertension, and medications used. Overweight was defined as BMI *Z*-score \> 1.0 and obesity as BMI *Z*-score \> 2.0. Corticosteroid doses were converted to prednisone dose (mg/kg/24 h). Five grade (I°-V°) WHO classification was used to evaluate kidney biopsy findings in IgAN/HSN patients \[[@ref20]\]. Serum concentrations of creatinine (mg/dl), uric acid (mg/dl), total, low-density (LDL) and high-density lipoprotein (HDL) cholesterol (mg/dl), triglycerides (mg/dl) were assessed. Proteinuria was evaluated in morning urine sample (mg/dl) and in daily urinary collection (mg/kg/24 h). Biochemical variables were measured using VITROS 5600 (Ortho Clinical Diagnostics, Linden, NJ, USA). Glomerular filtration rate (ml/min/1.73 m^2^) was calculated \[[@ref21]\] and stages of CKD were classified according to KDIGO classification \[[@ref18]\]. Impaired renal function was defined as GFR \< 90 ml/min/1.73m^2^. Hyperuricemia was defined as uric acid \> 6.0 mg/dl, hypoproteinemia as total protein \< 6.0 g/dl, hypoalbuminemia as albumin \< 3.5 g/dl, hypercholesterolemia as cholesterol ≥ 200 mg/dl, and hypertriglyceridemia as triglyceride ≥ 100 mg/dl (children aged 0-9 years) or ≥ 130 mg/dl (children aged 10-19 years) \[[@ref22]\], and nephrotic proteinuria as daily urinary protein loss ≥ 50 mg/kg/24 h.

Peripheral blood pressure (BP) was measured using Welch Allyn VSM Vital Sings Monitor 300 (Welch Allyn Inc., Skaneateles Falls, NY, USA), and expressed as mm Hg and *Z*-score \[[@ref23]\]. Central (aortic) blood pressure (AoBP) (mm Hg), augmentation index normalized to heart rate of 75 beats per minute (AIx75HR) (%), subendocardial viability ratio (SEVR) (%), and aortic pulse wave velocity (PWV) (m/s) were evaluated with Sphygmocor device (AtCor Medical Pty Ltd., Sydney, Australia), and common carotid intima-media thickness (cIMT) (mm) with Aloka Prosound Alpha 6 (Hitachi Aloka Medical, Mitaka, Japan) using 13-MHz linear transducer. Detailed methods of central blood pressure and arterial damage assessment have been described in our previous studies \[[@ref2], [@ref4]\]. PWV and cIMT were expressed as absolute values and *Z*-scores \[[@ref24], [@ref25]\]. Central systolic blood pressure (AoSBP) was compared with normative data \[[@ref26]\]. Peripheral and central BP, PWV, and cIMT ≥ 95^th^ percentile were considered abnormal.

All procedures were in accordance with ethical standards of the Institutional Bioethical Committee (approval No. KB/199/2012), and with 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all participants included in the study (≥ 16 years) and their representatives.

Statistical elaboration was performed using Dell Statistica 13.0 PL (Dell Inc., AlisoViejo, CA, USA). Variables were presented as absolute numbers and frequencies or mean ±standard deviation (SD). Normality of data was analyzed with Shapiro-Wilk test. Following tests were used (depending on data distribution): Student's *t*-test, U Mann-Whitney test, Spearman rank correlation, χ^2^ test, and Fisher's exact test. Multivariate analysis was performed using general regression model. Parameters that correlated with ADMA concentration in univariate analysis with *p* \< 0.100 together with markers of arterial damage (PWV *Z*-score, cIMT *Z*-score, and AIx75HR) were included in the model. A *p*-value \< 0.05 was considered statistically significant.

Results {#S3}
=======

The clinical characteristics of the study group are presented in [Table 1](#T1){ref-type="table"}. Patients with INS and patients with IgAN/HSN did not differ in sex, age, and BMI *Z*-score. Overweight was found in 19 (11 with INS, 8 with IgAN/HSN) and obesity in 17 (12 with INS, 5 with IgAN/HSN) participants. The duration of the disease was longer and prevalence of hypertension was more common in patients with INS. In the INS group, there were 17 steroid-resistant (SR) and 25 steroid-sensitive/steroid-dependent patients (SS/SD). Kidney biopsy was performed in 32/42 patients with INS -- minimal change disease was revealed in 4, mesangial proliferation in 22, and focal and segmental glomerulosclerosis in 6 children. In the IgAN/HSN group there were 16 patients with IgAN and 22 with HSN. Classification of kidney biopsy results according to WHO classification in IgAN/HSN group was as follows: 1 patient with class 1, 14 patients with class 2, 19 class 3, and 4 with class 4. Corticosteroids were used in comparable percentage of patients from both groups, but corticosteroid dose was significantly higher in IgAN/HSN group. There were also significant differences in usage of other immunosuppressive medications resulting from disease-specific protocols. Biochemical parameters are depicted in [Table 2](#T2){ref-type="table"}. The groups did not differ in GFR. Impaired renal function was found in 15 patients: CKD stage 2 was revealed in 13 children (7 with INS and 6 with IgAN/HSN) and CKD stage 3 in 2 children, with IgAN/HSN and GFR 41.60 and 57.48 ml/min/1.73 m^2^, respectively. Uric acid was significantly higher in INS children; hyperuricemia was found in 16 patients with INS and 11 with IgAN/HSN. The groups did not differ in terms of total protein, albumin, and lipids. Hypoproteinemia was found in 9 patients (5 with INS, 4 with IgAN/HSN), hypoalbuminemia in 13 (7 with INS, 6 with IgAN/HSN), hypercholesterolemia in 34 (17 with INS, 17 with IgAN/HSN), and hypertriglyceridemia in 30 (15 with INS, 15 with IgAN/HSN). At the moment of evaluation, 22 patients were proteinuric (7 with INS, 15 with IgAN/HSN) and 11 had nephrotic proteinuria (2 with INS, 9 with IgAN/HSN). Mean daily proteinuria was higher in IgAN/HSN group.

###### 

Clinical characteristics of the studied children

  Characteristics                   Study group   INS           IgAN/HSN      *p*^1^
  --------------------------------- ------------- ------------- ------------- ----------
  Number of patients                80            42            38            
  Boys/girls                        50/30         23/19         27/11         0.133
  Age, years                        11.33 ±4.25   10.81 ±4.36   11.91 ±4.09   0.219
  Duration of the disease, years    4.71 ±4.36    6.78 ±4.35    2.46 ±3.06    \< 0.001
  Number of relapses (INS)          --            8.11 ±5.88    --            --
  BMI Z-score                       0.87 ±1.09    0.96 ±1.17    0.77 ±1.011   0.850
  Arterial hypertension, n (%)      35 (43.8)     23 (54.8)     12 (31.6)     0.037
  Antihypertensive medications, n                                             
  ACEi                              60            31            29            0.796
  CCB                               11            5             6             0.614
  BB                                5             5             0             0.056
  HCTZ                              1             1             0             1.000
  Spironolactone                    1             1             0             1.000
  GC, n                             60            33            27            0.453
  GC, mg/kg/24 h                    0.58 ±0.58    0.39 ±0.45    0.79 ±0.65    0.006
  Immunosuppressant agents                                                    
  Cyclosporine                      25            23            2             \< 0.001
  Azathioprine                      11            0             11            \< 0.001
  Mycophenolate mofetil             12            12            0             \< 0.001
  Cyclophosphamide                  4             2             2             1.000
  Tacrolimus                        1             1             0             1.000

INS vs. IgAN/HSN, INS -- idiopathic nephrotic syndrome, IgAN -- IgA nephropathy, HSN -- Henoch-Schönlein nephropathy, BMI -- body mass index, ACEi -- angiotensin converting enzyme inhibitor, CCB -- calcium channel blocker, BB -- beta-blocker, HCZT -- hydrochlorothiazide, GC -- glucocorticoid

###### 

Biochemical data of the studied children

  Parameter                  Study group     INS             IgAN/HSN         *p* (INS vs. IgAN/HSN)
  -------------------------- --------------- --------------- ---------------- ------------------------
  GFR~S~, ml/min/1.73m^2^    109.29 ±24.50   109.12 ±17.64   109.47 ±30.63    0.627
  Uric acid, mg/dl           5.31 ±1.59      5.65 ±1.63      4.92 ±1.46       0.044
  Total protein, g/dl        6.79 ±0.90      6.67 ±0.85      6.89 ±0.94       0.215
  Albumin, g/dl              4.01 ±0.71      4.03 ±0.75      3.99 ±0.67       0.705
  Total cholesterol, mg/dl   224.97 ±88.52   243.55 ±97.30   209.82 ±78.73    0.098
  HDL cholesterol, mg/dl     68.91 ±22.82    72.62 ±26.22    65.91 ±19.49     0.468
  LDL cholesterol, mg/dl     127.55 ±74.42   140.21 ±76.70   117.62 ±72.06    0.113
  Triglycerides, mg/dl       140.92 ±91.14   151.40 ±99.37   132.65 ±84.51    0.345
  Proteinuria, mg/dl         83.24 ±174.70   60.93 ±148.90   107.97 ±198.62   0.477
  Proteinuria, mg/kg/24 h    22.00 ±39.33    13.75 ±34.85    31.58 ±42.53     0.004

INS -- idiopathic nephrotic syndrome, IgAN -- IgA nephropathy, HSN -- Henoch-Schönlein nephropathy, GFR~S~ -- glomerular filtration rate according to Schwartz formula, HDL -- high-density lipoprotein, LDL -- low-density lipoprotein

Concentration of ADMA, peripheral and central blood pressure as well as markers of arterial damage are presented in [Table 3](#T3){ref-type="table"}. Mean ADMA concentration was comparable in both groups of the patients ([Fig. 1](#F1){ref-type="fig"}). Patients with INS did not differ compared to IgAN/HSN patients in peripheral and central blood pressure, arterial stiffness, and cIMT. At the moment of evaluation, elevated peripheral systolic blood pressure was revealed in 11 subjects (6 with INS, with 5 IgAN/HSN), peripheral diastolic blood pressure in 6 (4 with INS, 2 with IgAN/HSN), and elevated central systolic blood pressure in 10 (5 with INS, 5 with IgAN/HSN). Abnormal PWV was revealed in 9 (6 with INS, 3 with IgAN/HSN) and abnormal cIMT in 20 patients (11 with INS, 9 with IgAN/HSN).

###### 

Asymmetric dimethylarginine, peripheral, and central blood pressure and markers of arterial damage in children with glomerular kidney diseases

  -------------------------------------------------------------------------------------------
  Parameter       Study group      INS              IgAN/HSN         *p* (INS vs. IgAN/HSN)
  --------------- ---------------- ---------------- ---------------- ------------------------
  ADMA, nmol/ml   1.66 ±1.21       1.72 ±1.24       1.60 ±1.19       0.958

  SBP, mm Hg\     114.51 ±12.27\   114.20 ±11.53\   114.89 ±13.34\   0.826\
  SBP Z-score     0.93 ±1.18       1.11 ±1.09       0.70 ±1.27       0.181

  DBP, mm Hg\     70.39 ±10.72\    70.37 ±10.91\    70.41 ±10.69\    0.868\
  DBP Z-score     0.84 ±0.92       0.94 ±0.96       0.72 ±0.87       0.256

  AoSBP, mm Hg    98.21 ±11.40     98.23 ±11.93     98.19 ±10.91     0.988

  AoDBP, mm Hg    72.06 ±10.77     72.29 ±10.86     71.77 ±10.85     0.853

  AoMAP, mm Hg    85.32 ±10.71     85.78 ±10.89     84.74 ±10.65     0.704

  AoPP, mm Hg     26.89 ±6.93      27.27 ±8.22      26.42 ±4.96      0.945

  AIx75HR, %      8.09 ±18.59      11.34 ±18.59     4.05 ±18.15      0.146

  SEVR, %         143.28 ±40.72    137.50 ±34.26    150.50 ±47.24    0.284

  PWV, m/s        4.90 ±0.75       4.80 ±0.6 8      5.02 ±0.82       0.251

  PWV Z-score     0.44 ±1.57       0.48 ±1.51       0.39 ±1.68       0.822

  cIMT, mm        0.45 ±0.06       0.45 ±0.05       0.45 ±0.07       0.948

  cIMT Z-score    1.44 ±1.17       1.53 ±1.14       1.30 ±1.23       0.461
  -------------------------------------------------------------------------------------------

INS -- idiopathic nephrotic syndrome, IgAN -- IgA nephropathy, HSN -- Henoch-Schönlein nephropathy, ADMA -- asymmetric dimethylarginine, SBP -- systolic blood pressure, DBP -- diastolic blood pressure, AoSBP -- aortic (central) systolic blood pressure, AoDBP -- aortic (central) diastolic blood pressure, AoMAP -- aortic (central) mean blood pressure, AoPP -- aortic (central) pulse pressure, AIx75HR -- augmentation index normalized to heart rate of 75 beats per minute, SEVR -- subendocardial viability ratio, PWV -- pulse wave velocity, cIMT -- common carotid artery intima-media thickness

![Asymmetric dimethylarginine in children with idiopathic nephrotic syndrome and IgA nephropathy/Henoch-Schönlein nephropathy (ADMA -- asymmetric dimethylarginine, INS -- idiopathic nephrotic syndrome, IgAN/HSN -- IgA nephropathy/Henoch-Schönlein nephropathy)](CEJI-44-39793-g001){#F1}

In the whole group of 80 patients, ADMA concentration did not differ between boys and girls (1.72 ±1.24 vs. 1.56 ±1.17 \[nmol/ml\], *p* = 0.777), between patients with and without arterial hypertension (1.62 ±1.18 vs. 1.69 ±1.24 \[nmol/ml\], *p* = 0.742), and between those with and without proteinuria (1.59 ±1.21 vs. 1.69 ±1.22 \[nmol/ml\], *p* = 0.616). Patients treated with corticosteroids had significantly lower ADMA concentration compared to those who were not receiving corticosteroids (1.51 ±1.16 vs. 2.12 ±1.27 \[nmol/ml\], *p* = 0.017) ([Fig. 2](#F2){ref-type="fig"}). There was no difference between those treated and not treated with ACEi (1.60 ±1.16 vs. 1.84 ±1.37 \[nmol/ml\], *p* = 0.894). Also, no relation between ADMA concentration and response to steroids (SS/SD vs. SR), result of kidney biopsy, sex, presence of arterial hypertension, presence of proteinuria, treatment with cyclosporine A, mofetil mycophenolate, and ACEi was found in children with INS (*p* = 0.818, *p* = 0.285, *p* = 0.324, *p* = 0.390, *p* = 0.380, *p* = 0.331, *p* = 0.358, and *p* = 0.290, respectively). Children with INS treated with corticosteroids had significantly lower ADMA compared to those who were not treated (1.55 ±1.19 vs. 2.38 ±1.29 \[nmol/ml\], *p* = 0.040). In IgAN/HSN, no relation between ADMA and extent of disease (renal limited -- IgAN vs. systemic -- HSN), WHO classification, sex, presence of arterial hypertension, presence of proteinuria, treatment with corticosteroids, azathioprine, and ACEi was revealed (*p* = 0.712, *p* = 0.562, *p* = 0.342, *p* = 0.572, *p* = 0.823, *p* = 0.240, *p* = 0.723, and *p* = 0.250, respectively).

![Asymmetric dimethylarginine in children with glomerular kidney diseases treated and not treated with glucocorticoids (ADMA -- asymmetric dimethylarginine, GC -- glucocorticoid)](CEJI-44-39793-g002){#F2}

Correlations of ADMA with clinical and biochemical parameters and with blood pressure and markers of arterial damage are presented in [Table 4](#T4){ref-type="table"}. In the whole group, we found negative correlations of ADMA with BMI *Z*-score, uric acid, HDL-cholesterol, and central mean arterial pressure. In addition, in patients with INS, ADMA correlated positively with total protein and albumin, and negatively with total cholesterol. ADMA showed no correlation with renal function (GFR). Also, no correlation was found when we analyzed only those 15 individuals with impaired renal function (*r* = 0.09, *p* = 0.796). No association was revealed between ADMA and corticosteroid dose in the treated patients. In whole group and also in subgroups of patients with INS and IgAN/HSN, no significant correlations were found between serum ADMA concentration and markers of arterial damage: AIx, PWV, and cIMT. Similarly, no significant correlations between ADMA and aforementioned markers were revealed in subgroups of proteinuric and non-proteinuric patients. Results of multivariate analysis are reported in [Table 5](#T5){ref-type="table"}. Serum albumin was the strongest determinant of ADMA in patients with glomerular kidney diseases (β = 0.536, 95% CI: 0.013-1.060, *p* = 0.045).

###### 

Correlations of ADMA in children with glomerular kidney diseases with selected clinical and biochemical parameters, with blood pressure and markers of arterial damage

  Analyzed parameter           Correlation with ADMA (*R*, *p*)                   
  ---------------------------- ---------------------------------- --------------- ---------------
  Age, years                   --0.07, 0.522                      --0.11, 0.481   --0.11, 0.530
  Duration of the disease, n   0.06, 0.613                        0.00, 0.999     0.08, 0.619
  Number of relapses (INS)     --                                 --0.04, 0.804   --
  BMI Z-score                  --0.24, 0.035                      --0.23, 0.150   --0.24, 0.155
  CS, mg/kg/24 h               --0.10, 0.463                      --0.16, 0.379   0.03, 0.880
  GFR~S~, ml/min/1.73m^2^      0.15, 0.184                        0.20, 0.212     0.21, 0.202
  Uric acid, mg/dl             --0.23, 0.042                      --0.35, 0.024   --0.15, 0.377
  Total protein, g/dl          0.19, 0.102                        0.36, 0.030     --0.04, 0.820
  Albumin, g/dl                0.21, 0.071                        0.37, 0.022     --0.03, 0.877
  Total cholesterol, mg/dl     --0.21, 0.078                      --0.40, 0.028   --0.05, 0.781
  HDL cholesterol, mg/dl       --0.25, 0.045                      --0.32, 0.085   --0.16, 0.332
  LDL cholesterol, mg/dl       --0.09, 0.473                      --0.32, 0.090   0.13, 0.432
  Triglycerides, mg/dl         --0.23, 0.061                      --0.32, 0.083   --0.09, 0.595
  Proteinuria, mg/dl           --0.01, 0.898                      --0.09, 0.564   0.05, 0.763
  Proteinuria, mg/kg/24 h      0.04, 0.763                        --0.03, 0.846   0.06, 0.729
  SBP, mm Hg                   --0.18, 0.156                      --0.21, 0.218   --0.16, 0.427
  SBP Z-score                  --0.20, 0.118                      --0.22, 0.199   --0.16, 0.438
  DBP, mm Hg                   --0.14, 0.286                      --0.17, 0.323   --0.11, 0.569
  DBP Z-score                  --0.09, 0.464                      --0.08, 0.651   --0.10, 0.605
  AoSBP, mm Hg                 --0.22, 0.081                      --0.20, 0.245   --0.28, 0.146
  AoDBP, mm Hg                 --0.20, 0.109                      --0.20, 0.260   --0.20, 0.317
  AoMAP, mm Hg                 --0.25, 0.045                      --0.25, 0.154   --0.24, 0.218
  AoPP, mm Hg                  --0.12, 0.339                      --0.20, 0.238   0.00, 0.982
  AIx75HR, %                   --0.16, 0.226                      --0.22, 0.238   0.01, 0.965
  SEVR, %                      0.13, 0.295                        0.11. 0.547     0.16, 0.424
  PWV, m/s                     --0.04, 0.747                      --0.03, 0.870   --0.10, 0.608
  PWV Z-score                  --0.08, 0.557                      0.03, 0.874     --0.20, 0.321
  cIMT, mm                     0.03, 0.795                        0.10, 0.580     --0.12, 0.562
  cIMT Z-score                 0.01, 0.946                        0.09, 0.930     --0.13, 0.538

INS -- idiopathic nephrotic syndrome, IgAN -- IgA nephropathy, HSN -- Henoch-Schönlein nephropathy, ADMA -- asymmetric dimethylarginine, BMI -- body mass index, GC -- glucocorticoid, GFR~S~ -- glomerular filtration rate according to Schwartz formula, HDL -- high-density lipoprotein, LDL -- low-density lipoprotein, SBP -- systolic blood pressure, DBP -- diastolic blood pressure, AoSBP -- aortic (central) systolic blood pressure, AoDBP -- aortic (central) diastolic blood pressure, AoMAP -- aortic (central) mean blood pressure, AoPP -- aortic (central) pulse pressure, AIx75HR -- augmentation index normalized to heart rate of 75 beats per minute, SEVR -- subendocardial viability ratio, PWV -- pulse wave velocity, cIMT -- common carotid artery intima-media thickness

###### 

Multivariate analysis of factors influencing concentration of ADMA including markers of arterial damage

  Analyzed parameter         β         95% confidence interval   *p*
  -------------------------- --------- ------------------------- -------
  Albumin, g/dl              0.536     0.013-1.060               0.045
  BMI Z-score                --0.386   --0.808-0.035             0.071
  AIx75HR, %                 --0.277   --0.682-0.127             0.170
  cIMT Z-score               --0.194   --0.570-0.183             0.299
  AoMAP, mm Hg               --0.493   --1.528-0.543             0.336
  PWV Z-score                0.194     --0.227-0.616             0.351
  Total cholesterol, mg/dl   0.251     --0.597-1.099             0.548
  AoSBP, mm Hg               0.186     --0.723-1.096             0.676
  Uric acid, mg/dl           0.090     --0.354-0.534             0.679
  Triglycerides, mg/dl       0.120     --0.477-0.718             0.682
  Glucocorticoids (yes/no)   --0.07    --0.544-0.407             0.769
  HDL cholesterol, mg/dl     --0.01    --0.416-0.393             0.953

ADMA -- asymmetric dimethylarginine, BMI -- body mass index, AIx75HR -- augmentation index normalized to heart rate of 75 beats per minute, cIMT -- common carotid artery intima-media thickness, AoMAP -- aortic (central) mean blood pressure, PWV -- pulse wave velocity, AoSBP -- aortic (central) systolic blood pressure, HDL -- high-density lipoprotein

Discussion {#S4}
==========

Results of our study did not show any significant relation between ADMA concentration and either thickening of arterial wall (cIMT) or parameters of arterial stiffness (PWV and AIx75HR) in both univariate and multivariate analysis. We found negative correlation of ADMA with central mean arterial pressure, BMI *Z*-score, and uric acid. In addition, in patients with INS, ADMA correlated with typical biochemical disturbances: positively with total protein and albumin, and negatively with total cholesterol. Serum albumin concentration was the strongest predictor of ADMA.

We did not find significant relations between ADMA and sex or age. ADMA concentration was inversely related to BMI *Z*-score in univariate model. In pediatric patients with primary hypertension, ADMA was positively related to waist-hip ratio and was significantly higher in those with metabolic syndrome, though no direct correlation with BMI was shown \[[@ref14]\]. In another study, ADMA was positively associated with BMI *Z*-score in hyperuricemic adolescents \[[@ref27]\]. On the contrary, Japanese authors observed significantly lower ADMA in obese patients compared to lean children \[[@ref28]\]. There is a strong pathophysiological link between elevated serum uric acid and endothelial dysfunction. Uric acid was shown to damage directly endothelial cells. Both uric acid and ADMA were found to decrease NO production in these cells \[[@ref29], [@ref30]\]. Indeed, a positive correlation between serum ADMA and uric acid was depicted in pediatric hyperuricemic patients \[[@ref27]\]. On contrary, uric acid was inversely related to ADMA in our cohort. It is possible that the relation between body mass, uric acid, and ADMA is overridden in patients with glomerulopathies by other factors (e.g. dysproteinemia), especially in case of immunosuppressive treatment.

Kidneys provide a significant route for clearance of methylarginines. Thus, it is not surprising that ADMA concentrations increase in patients with CKD \[[@ref8], [@ref9]\]. In our cohort, we have not found any significant association between serum ADMA level and GFR. This discrepancy may be due to the fact that only small subgroup of our subjects showed mild to moderate impairment of renal function and we excluded patients with CKD stages 4 and 5. Similarly to our results, no difference was found in terms of ADMA level between pediatric patients with normal kidney function and CKD stages 2 and 3 \[[@ref16]\].

In 42 patients with nephrotic syndrome, ADMA was positively related to level of proteins and negatively to total cholesterol. Additionally, in multivariate analysis, albumin level was the strongest predictor of ADMA in the whole group. It must be emphasized that most of our patients with INS were in remission of the disease. Nevertheless, many of them were tested within a month after last relapse and had slightly lowered albumin and elevated cholesterol. Our results are in accordance with the study by Hyla-Klekot who found positive correlations of ADMA, with total protein (in remission phase) and negative correlations with triglycerides and cholesterol (in relapse phase) \[[@ref13]\]. In physiological state, 90% of ADMA is bound to albumin \[[@ref10]\]. Thus, loss of albumins would directly impact total ADMA blood concentration, similarly to other albumin-bound small-molecular-weight molecules.

In contrast to numerous population studies in adults \[[@ref11]\], we found negative correlation between ADMA and cholesterol. It is hypothesized that high-concentrations of LDL, especially ox-LDL, increase expression of the methyltransferase gene (responsible for ADMA synthesis) and suppression of DDAH activity \[[@ref10]\]. It is probable that in patients with glomerulopathies, protein disturbances override this mechanism. Hyla-Klekot suggested also that liver hyperactivity, observed in INS, promotes expression of DDAH \[[@ref13]\]. This would strengthen negative correlation between cholesterol (and apolipoproteins) and ADMA.

We did not find any relation between extent of protein loss and ADMA in the studied children as well as in subgroups with INS and IgAN/HSN. This finding supports thesis that ADMA is dependent rather on serum protein concentration, not on its loss. On the contrary, Yilmaz *et al*. found strong positive correlation (*r* = 0.88, *p* \< 0.001) between ADMA and daily urinary protein loss \[[@ref31]\]. It is noteworthy that those patients were also characterized by hypoalbuminemia, and relation between ADMA and serum albumin was not analyzed.

We found significantly lower ADMA levels in patients treated with GC, though this relation was not dose-dependent and was not confirmed in multivariate model. Similar results were found in children with Duchenne muscular dystrophy \[[@ref32]\]. On the contrary, Japanese authors showed significant rise in ADMA concentration in 14 young adult individuals with IgAN, treated with GC pulse therapy \[[@ref33]\]. Glucocorticoids exert cardiovascular and neuronal protection through a non-transcriptional activation of endothelial nitric oxide synthase (eNOS) in mice \[[@ref34]\]. In contrast, GC excess may induce superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. It is hypothesized that GCs may affect endothelial function either favorably or harmfully, depending on dose and route of administration. Angiotensin converting enzyme inhibitors are antihypertensive drugs with potent vasoprotective actions, and were found to decrease ADMA in adults with CKD \[[@ref35]\]. In our cohort, there was no difference in ADMA level between those treated and not treated with these medications. This negative finding could be explained by small number of untreated patients (*n* = 20), short treatment duration, and lack of prospective analysis of the subjects.

In general population, ADMA levels are independently associated with endothelial dysfunction \[[@ref36]\], subclinical arterial damage \[[@ref7], [@ref37], [@ref38]\], and all-cause mortality \[[@ref12]\]. ADMA was found to correlate positively with arterial stiffness in adult patients with hypertension (AIx75HR) \[[@ref37]\], prediabetes (PWV) \[[@ref38]\], and in elderly general population (AIx75HR) \[[@ref7]\]. As ADMA levels increase in CKD as a consequence of impaired renal clearance, this negative relation should strengthen alongside with kidney function decline. Indeed, meta-analysis of studies in adult patients with CKD showed strong positive correlation between ADMA and cIMT \[[@ref8]\]. Finally, Zoccali showed that ADMA is the second strongest (after age) predictor of all-cause and cardiovascular mortality in adults with end-stage renal disease \[[@ref11]\].

In our study group, we found no associations between ADMA and any of the measured markers of subclinical arterial damage. It must be stressed that our patients had already been affected by cardiovascular disease, as 43.8% of them had arterial hypertension, 20% had abnormally thickened cIMT, and 11.3% abnormal PWV. Results of our previous studies suggest that in this group of patients, other factors like number of INS relapses, disease vintage, cumulative steroid dose, body mass index, presence of arterial hypertension, and maybe overexpression of renalase, influence arterial damage \[[@ref2]-[@ref4]\]. Our results do not support usage of ADMA as a marker of arterial damage in pediatric patients with glomerular kidney diseases. It is worth to mention that significance of ADMA as a biomarker of vascular damage in pediatric population remains questionable. Although ADMA was significantly and independently associated with cIMT in a group of 405 8-year-old Australian children \[[@ref39]\], this relation was not confirmed in high-risk patients. ADMA level did not correlate with cIMT in pediatric patients with primary hypertension \[[@ref14]\], with cIMT, PWV, and ambulatory arterial stiffness index (AASI) in children with CKD stages 1-3 \[[@ref16]\], with cIMT in children with CKD stages 2-5 \[[@ref17]\], or with cIMT, PWV, and AIx75HR in children with juvenile idiopathic arthritis \[[@ref15]\].

Interestingly, in our cohort, ADMA correlated negatively with mean central blood pressure. Central blood pressure is considered a better predictor of cardiovascular events in comparison to peripheral blood pressure, as vital organs (heart, kidneys, and brain) are exposed to aortic pressure. An experimental study demonstrated that intravenously dosed ADMA could significantly increase blood pressure \[[@ref40]\]. On the other hand, parallel to our results, ADMA concentration was inversely related to blood pressure, vascular resistance, and PWV in young healthy population from young Finns study. The authors suggest that in the young people, ADMA could be a beneficial molecule responsible for maintaining appropriate vascular resistance \[[@ref41]\]. Finally, negative correlations of ADMA with uric acid, BMI *Z*-score, and central mean arterial pressure might suggest even a protective role of this molecule in children with glomerular kidney diseases. Similarly, lower ADMA was found in children with diabetes mellitus type 1 compared to healthy peers \[[@ref28], [@ref42]\]. In these patients, Huemer observed negative correlation of ADMA with blood pressure, similar as in our cohort \[[@ref42]\]. The relationship between ADMA and cardiovascular physiology in the young is not yet fully understood and requires further studies.

Several limitations of our study should be discussed. Firstly, we have not analyzed ADMA concentrations in healthy individuals. Secondly, the cross-sectional nature of the study prevents firm conclusions on causal relationship between ADMA and analyzed parameters. Also, the study group was not large and not uniform in terms of treatment and disease vintage.

Conclusions {#S5}
===========

In children with glomerulonephritis, the measurement of asymmetric dimethylarginine cannot replace well established and validated methods of assessment of subclinical arterial damage.

In children with glomerular kidney diseases, ADMA concentration is related primarily to serum albumin concentration.
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